|Contact Us||+41 21 691 43 email@example.com||EPFL Innovation Park|
|+41 21 691 43 75|
|EPFL Innovation Park|
Evaluates risks of thrombosis under contraceptive pills
Pill Protect® is an ingenious CE-IVD marked medical test that uses genetic and clinical data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. It is the first clinically validated test and the best performing tool to identify women at risk of developing thrombosis under contraceptive pills.
The genetic profiles that everybody should have
Cypass® and Extended Cypass® are innovative genetic tests that evaluate overall risk of adverse drug events. They integrate patient’s abilities to activate and eliminate drugs with drug-drug interactions simultaneously, thus allowing selecting for safer and more effective drug regimens that can improve drug treatment outcomes and reduce or avoid adverse drug reactions.
The test that allows matching nutrition to genes
Nutripass® is an exhaustive genetic and nutritional analysis that allows to tailor dietary habits and helps to optimize and improve health.
Genetic test assessing the risk of developing certain autoimmune disorders such as ankylosing spondylitis, reactive arthritis (Reiter’s Syndrome), psoriatic arthritis, ulcerative colitis associated spondyloarthritis, anterior uveitis and iritis.
A classical undiagnosed problem. Look for genetic variants linked to gluten impaired metabolisation.
Analysis of genetic variants in MTHFR gene associated with high homocysteine levels.